Scarica l'app Stockscreener
2.90
2.11%
0.06
Dopo l'orario di chiusura:
2.90
Precedente Chiudi:
$2.84
Aprire:
$2.94
Volume 24 ore:
8,390
Relative Volume:
0.30
Capitalizzazione di mercato:
$29.55M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.1474
EPS:
-19.67
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-1.02%
1M Prestazione:
-2.36%
6M Prestazione:
-19.22%
1 anno Prestazione:
-47.09%
Intervallo 1D:
$2.90
$3.2038
Intervallo di 1 settimana:
$2.74
$3.2038
Portata 52W:
$2.37
$5.50
Polypid Ltd Stock (PYPD) Company Profile
Confronta PYPD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
2.90 | 29.55M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
Major Breakthrough: DSMB Backs Early Completion of Surgical Infection Prevention Trial - StockTitan
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
PolyPid Ltd. Earnings Call Highlights Promising Prospects - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook - TipRanks
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 - MSN
PolyPid Updates: New Board Appointment and SHIELD II Trial Progress - TipRanks
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times
PolyPid's Phase 3 Trial Nears Completion: Key Financial Updates Reveal Path to Critical Q2 2025 Results - StockTitan
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
Rodman & Renshaw sets PolyPid stock at Buy with $13 target - MSN
PolyPid Regains Nasdaq Compliance with Private Placement Boost - TipRanks
Surgical Site Infections Pipeline 2024: Key Companies, MOA, - openPR
Critical Survey: InfuSystem (NYSE:INFU) vs. PolyPid (NASDAQ:PYPD) - Defense World
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress - Investing.com India
PolyPid Ltd. announced that it expects to receive $14.470133 million in funding - Marketscreener.com
FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Price Target Lowered to $11.00 at HC Wainwright - Defense World
PolyPid Advances Phase 3 Trial and Secures Financing - TipRanks
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright - Investing.com Australia
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright By Investing.com - Investing.com South Africa
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - The Manila Times
PolyPid's Surgical Infection Drug Trial Advances with $14.5M Funding Boost; Phase 3 Results Due Q2 2025 - StockTitan
FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):